LifeSciences BC > News > Member Announcements > Page 2

Aquinox Promotes Lloyd Mackenzie to Chief Operating Officer and Vice President, R&D Operations

December 15, 2017
Aquinox Pharmaceuticals, Inc.

VANCOUVER, British Columbia, Dec. 15, 2017 (GLOBE NEWSWIRE) — Aquinox Pharmaceuticals, Inc. (“Aquinox”) (NASDAQ:AQXP) today announced that Lloyd Mackenzie has been promoted, effective immediately, to the newly created position of Chief Operating Officer and Vice President, R&D Operations. “As we focus on executing the clinical development plan for rosiptor, our lead drug candidate, this is … Continue reading Aquinox Promotes Lloyd Mackenzie to Chief Operating Officer and Vice President, R&D Operations

Leading Organizations in the Pacific Northwest Sign MOU for Cascadia Venture Acceleration Network, a Partnership to Fuel Innovation

December 11, 2017

Today, nearly 50 organizations in the Pacific Northwest convened at Cambia Grove in Seattle to sign a memorandum of understanding (MOU) establishing the Cascadia Venture Acceleration Network, a partnership of incubators, accelerators, universities, investors and industry associations that have pledged to work collaboratively in support of entrepreneurs and researchers across British Columbia, Washington state and … Continue reading Leading Organizations in the Pacific Northwest Sign MOU for Cascadia Venture Acceleration Network, a Partnership to Fuel Innovation

Aequus announces the issuance of stock options

December 11, 2017
Aequus Pharmaceuticals Inc.

VANCOUVER, December 8, 2017 – Aequus Pharmaceuticals Inc. (TSX-V: AQS, OTCQB: AQSZF) (“Aequus” or the “Company”), a specialty pharmaceutical company with a focus on developing, advancing and promoting differentiated products, today announced the issuance of stock options to directors, officers, staff and consultants.  The stock options give the holders the right to purchase up to … Continue reading Aequus announces the issuance of stock options

Aquinox Statement on FDA Advisory Committee Meeting to Discuss Interstitial Cystitis/Bladder Pain Syndrome (IC/BPS)

December 8, 2017
 Aquinox Pharmaceuticals, Inc.

Bone, Reproductive, and Urologic Drugs Advisory Committee Votes Unanimously  in Favor of Unified IC/BPS Population for Clinical Trials – SILVER SPRING, Md., Dec. 07, 2017 (GLOBE NEWSWIRE) — Aquinox Pharmaceuticals, Inc. (“Aquinox“) (NASDAQ:AQXP), a clinical-stage pharmaceutical company discovering and developing targeted therapeutics in disease areas of inflammation and immuno-oncology, today issued the following statements following the U.S. Food … Continue reading Aquinox Statement on FDA Advisory Committee Meeting to Discuss Interstitial Cystitis/Bladder Pain Syndrome (IC/BPS)

NASA Research Announcement (NRA) 80JSC017N0001-BPBA – Topics in Biological, Physiological, and Behavioral Adaptations to Spaceflight: Integrated One Year Mission Project and Other Opportunities

December 6, 2017
Canadian Space Agency

The Canadian Space Agency (CSA) would like to inform the Canadian Health and Biomedical community of the release of a NASA Research Announcement (NRA). NASA’s Human Research Program (HRP) released Appendix C of the Human Exploration Research Opportunities (HERO) NRA on November 30, 2017. This NASA Research Announcement solicits proposals to study International Space Station … Continue reading NASA Research Announcement (NRA) 80JSC017N0001-BPBA – Topics in Biological, Physiological, and Behavioral Adaptations to Spaceflight: Integrated One Year Mission Project and Other Opportunities

Positive Preclinical Data from Xenon’s XEN901 Epilepsy Program to be Presented at the 71st American Epilepsy Society Annual Meeting

December 5, 2017
Xenon Pharmaceuticals Inc.

Data Suggest Xenon’s Selective Nav1.6 Sodium Channel Inhibitor, XEN901, Provides Efficacy with a Potentially Improved Safety Profile over Other Non-Selective, Sodium Channel Blocker Anti-Epileptic Drugs (AEDs) BURNABY, British Columbia, Dec. 04, 2017 (GLOBE NEWSWIRE) — Xenon Pharmaceuticals Inc. (NASDAQ:XENE), a clinical-stage biopharmaceutical company, today announced the presentation of a scientific poster entitled “Selective Inhibitors Suggest Nav1.6 … Continue reading Positive Preclinical Data from Xenon’s XEN901 Epilepsy Program to be Presented at the 71st American Epilepsy Society Annual Meeting

Phyton Biotech Wins Grant to Develop New Approaches to Manufacturing Artemisinin

December 4, 2017
Phyton Biotech

Bill & Melinda Gates Foundation Invests in R&D Pilot for Anti-Malarial Active Pharmaceutical Ingredients AHRENSBURG, Germany, November 29, 2017 – Phyton Biotech today announced that it has received a $400,000 grant from the Bill & Melinda Gates Foundation to fund the research and development of an alternative method of producing artemisinin, a key active pharmaceutical … Continue reading Phyton Biotech Wins Grant to Develop New Approaches to Manufacturing Artemisinin

Aequus Provides Third Quarter 2017 Operational Highlights

November 29, 2017
Aequus Pharmaceuticals Inc.

VANCOUVER, November 29, 2017 – Aequus Pharmaceuticals Inc. (TSX-V: AQS, OTCQB: AQSZF) (“Aequus” or the “Company”), a specialty pharmaceutical company with a focus on developing, advancing and promoting differentiated products, today reported financial results for the three months ended September 30, 2017 and associated Company developments. Unless otherwise noted, all figures are in Canadian currency. … Continue reading Aequus Provides Third Quarter 2017 Operational Highlights

Discovery of Innate Immune Mechanisms of a Novel Microbial-based Approach for the Treatment of Lung Cancer

November 29, 2017
Qu Biologics Inc.

Vancouver, British Columbia – November 28th, 2017 Qu Biologics Inc. (Qu), a biopharmaceutical company developing Site Specific Immunomodulators (SSIs), a unique platform of immunotherapies designed to “reboot” the body’s innate immune system, has just published collaborative research with Dartmouth College detailing the mechanism of action and efficacy of Qu’s lung-targeted SSI, QBKPN, for the treatment … Continue reading Discovery of Innate Immune Mechanisms of a Novel Microbial-based Approach for the Treatment of Lung Cancer

Arbutus Announces Presentations at HepDART 2017

November 27, 2017
Arbutus Biopharma Corporation

VANCOUVER, British Columbia and WARMINSTER, Pa., Nov. 27, 2017 (GLOBE NEWSWIRE) — Arbutus Biopharma Corporation (Nasdaq:ABUS), an industry-leading Hepatitis B Virus (HBV) therapeutic solutions company, today announced two oral presentations and one poster presentation at HepDART 2017 being held on December 3 – 7, 2017 in Kona, Hawaii. Presentations Include: Oral Presentation: “Controlling HBsAg as a Key Component of a Combination Strategy to Affect … Continue reading Arbutus Announces Presentations at HepDART 2017